Results 1 to 10 of about 172,086 (187)

p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia [PDF]

open access: yesHaematologica, 2012
Background The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome. The p185BCR/ABL or the p210BCR/ABL fusion proteins are encoded as a result
Afsar A. Mian   +5 more
doaj   +4 more sources

MOLECULAR RELAPSE OF ACUTE PROMYELOCYTIC LEUKEMIA AFTER COMPLETE REMISSION: A CASE REPORT AND LITERATURE REVIEW [PDF]

open access: yes精准医学杂志, 2023
Objective To investigate the molecular biological changes of relapsed acute promyelocytic leukemia (APL), and to provide guidance for the clinical diagnosis and treatment of relapsed APL.
CHEN Junru, WANG Yilin, WANG Lingzhen, JIANG Jian, SUN Yan, LU Yuan
doaj   +1 more source

Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins

open access: yesBlood Cancer Discovery, 2021
Abstract The PML/RARα fusion protein is the oncogenic driver in acute promyelocytic leukemia (APL). Although most APL cases are cured by PML/RARα-targeting therapy, relapse and resistance can occur due to drug-resistant mutations.
Yasen Maimaitiyiming   +38 more
openaire   +2 more sources

Genetic fusions favor tumorigenesis through degron loss in oncogenes

open access: yesNature Communications, 2021
Chromosomal rearrangements can generate genetic fusions composed of two distinct gene sequences, many of which have been implicated in tumorigenesis and progression.
Jing Liu   +7 more
doaj   +1 more source

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

open access: yesInternational Journal of Molecular Sciences, 2023
CD74 is a type II cell surface receptor found to be highly expressed in several hematological and solid cancers, due to its ability to activate pathways associated with tumor cell survival and proliferation. Over the past 16 years, CD74 is emerging as a commonly detected fusion partner in multiple oncogenic fusion proteins.
Jasmine Vargas, Georgios Pantouris
openaire   +2 more sources

Adenoid cystic carcinoma: emerging role of translocations and gene fusions. [PDF]

open access: yes, 2016
Adenoid cystic carcinoma (ACC), the second most common salivary gland malignancy, is notorious for poor prognosis, which reflects the propensity of ACC to progress to clinically advanced metastatic disease.
Brait, Mariana   +5 more
core   +6 more sources

The fusion partner specifies the oncogenic potential of NUP98 fusion proteins [PDF]

open access: yesLeukemia Research, 2013
NUP98 is among the most promiscuously translocated genes in hematological diseases. Among the 28 known fusion partners, there are two categories: homeobox genes and non-homeobox genes. The homeobox fusion partners are well-studied in animal models, resulting in HoxA cluster overexpression and hematological disease.
Saw, J   +5 more
openaire   +3 more sources

Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing [PDF]

open access: yesProceedings of the National Academy of Sciences, 2007
MicroRNAs (miRNAs) are noncoding small RNA of ≈22 bases, which suppress expression of target genes through translational block or degradation of a target's transcript. Recent studies uncovered specific miRNA expression profiles in human malignancies.
Tatsuya Nakamura   +2 more
openaire   +3 more sources

Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML

open access: yesNature Communications, 2020
The oncogene MLL is frequently translocated in leukemia, resulting in oncogenic fusion proteins. Here, the authors report a temporally controlled mouse model of MLL-ENL driven leukemia AND identify therapeutic targets associated with early MLL-ENL driven
Silvia Basilico   +13 more
doaj   +1 more source

The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1. [PDF]

open access: yesPLoS ONE, 2009
This study demonstrates deregulation of polycomb activity by the synovial sarcoma-associated SYT-SSX2 oncogene, also known as SS18-SSX2. Synovial sarcoma is a soft tissue cancer associated with a recurrent t(X:18) translocation event that generates one ...
Roy Barco   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy